TuHURA Biosciences (HURA) Price & Analysis

Compare

974 Followers

HURA Stock Chart & Stats

$0.76

-$0.03(-0.55%)

At close: Jan 08 4:00 PM EST

$0.76

-$0.03(-0.55%)

Day’s Range― - ―

52-Week Range$0.70 - $5.27

Previous CloseN/A

Volume116.05K

Average Volume (3M)215.15K

Market Cap

$46.17M

Enterprise Value$91.68M

Total Cash (Recent Filing)$8.51M

Total Debt (Recent Filing)$558.97K

Price to Earnings (P/E)―

Beta1.36

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding60,720,510

10 Day Avg. Volume212,396

30 Day Avg. Volume215,145

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)5.23

Price to Sales (P/S)0.00

P/FCF Ratio-5.16

Enterprise Value/Market Cap1.99

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.20K

Enterprise Value/Ebitda-5.34

Forecast

1Y Price Target

$9.00

Price Target Upside1084.21% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

ADC DevelopmentSelection of a lead VISTA/delta receptor antibody drug conjugate with a differentiated mechanism could create a novel therapeutic option and attract partnership interest.

Anti‑VISTA Combination PotentialPositive interim data showing benefit for the anti‑VISTA antibody combined with a menin inhibitor in a specific AML genetic subtype could meaningfully expand the addressable patient population.

Pivotal Trial OutcomeSuccessful pivotal IFx-2.0 results in advanced skin cancer could support accelerated approval based on overall response rate and become a major value driver.

Bears Say

Competitive PressureCompetition from other checkpoint inhibitors could limit market uptake for VISTA-directed and IFx-2.0 programs if competing therapies demonstrate superior efficacy or safety.

Dilution RiskPlanned financings and capital raises may dilute existing shareholders and exert downward pressure on the share price.

Regulatory And Development SetbacksNegative clinical results or delays in development could lead to regulatory setbacks and materially reduce investor confidence in the pipeline.

TuHURA Biosciences News

TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on TuHURA Biosciences (HURA) to $10 from $12...

9d ago

HURA

TuHURA Biosciences announces release of Kintara’s CVR

TuHURA Biosciences (HURA) announced that Kintara’s REM-001 clinical trial of ten metastatic cutaneous breast cancer patients met its...

1M ago

HURA

TuHURA Biosciences provides updates across portfolio

TuHURA Biosciences (HURA) provided updates across the company’s portfolio of assets, including a summary from its mini symposium...

1M ago

HURA

TuHURA Biosciences Announces Securities Purchase Agreement

TuHURA Biosciences ( ($HURA) ) has provided an announcement. On December 9, 2025, TuHURA Biosciences announced a securities...

1M ago

HURA

TuHURA Biosciences announces $15.6M registered direct offering

TuHURA Biosciences (HURA) announced that it has entered into a definitive agreement for the purchase of an aggregate...

1M ago

HURA

TuHURA Biosciences presents research on potential role of DOR at ASH

TuHURA Biosciences (HURA) announced that its research on the potential role of the Delta Opioid Receptor in controlling...

1M ago

HURA

TuHURA Biosciences Amends Loan Agreement, Secures Full $3M

The latest update is out from TuHURA Biosciences ( ($HURA) ). TuHURA Biosciences, Inc. entered into a Secured...

1M ago

HURA

TuHURA Biosciences’ Shelf Registration Statement Effective

The latest announcement is out from TuHURA Biosciences ( ($HURA) ). On November 22, 2025, TuHURA Biosciences, Inc.’s...

2M ago

HURA

TuHURA Biosciences Completes Acquisition of Kineta, Inc.

TuHURA Biosciences ( ($HURA) ) has issued an update. On June 30, 2025, TuHURA Biosciences completed its acquisition...

2M ago

HURA

TuHURA Biosciences Reports Q3 Financials and Advances Cancer Therapy Trials

An update from TuHURA Biosciences ( ($HURA) ) is now available. TuHURA Biosciences has reported its third-quarter financial...

2M ago

HURA

TuHURA Biosciences price target lowered to $8 from $15 at Maxim

Maxim lowered the firm’s price target on TuHURA Biosciences (HURA) to $8 from $15 and keeps a Buy...

2M ago

HURA

TuHURA Biosciences Announces $50M Stock Offering Agreement

An announcement from TuHURA Biosciences ( ($HURA) ) is now available. On November 3, 2025, TuHURA Biosciences entered...

3M ago

HURA

TuHURA Biosciences files $250M mixed securities shelf

17:33 EST TuHURA Biosciences (HURA) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

HURA

TuHURA Biosciences Plans Phase 2 Trial for TBS-2025

An update from TuHURA Biosciences ( ($HURA) ) is now available. In June 2025, TuHURA Biosciences initiated a...

3M ago

HURA

HURA FAQ

What was TuHURA Biosciences’s price range in the past 12 months?

TuHURA Biosciences lowest stock price was $0.70 and its highest was $5.27 in the past 12 months.

What is TuHURA Biosciences’s market cap?

TuHURA Biosciences’s market cap is $46.17M.

When is TuHURA Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were TuHURA Biosciences’s earnings last quarter?

Currently, no data Available

Is TuHURA Biosciences overvalued?

According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TuHURA Biosciences pay dividends?

TuHURA Biosciences does not currently pay dividends.

What is TuHURA Biosciences’s EPS estimate?

TuHURA Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TuHURA Biosciences have?

TuHURA Biosciences has 60,720,510 shares outstanding.

What happened to TuHURA Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of TuHURA Biosciences?

Currently, no hedge funds are holding shares in HURA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

TuHURA Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-418.06%

Trailing 12-Months

Asset Growth

1736.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TuHURA Biosciences

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

TuHURA Biosciences (HURA) Earnings & Revenues

Historic Earnings Reports

HURA Stock 12 Month Forecast

Average Price Target

$9.00

▲(1084.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"142":"$142","-1":"-$1","34.75":"$34.8","70.5":"$70.5","106.25":"$106.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,34.75,70.5,106.25,142],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.756,1.467076923076923,2.178153846153846,2.8892307692307693,3.600307692307692,4.311384615384616,5.022461538461538,5.733538461538462,6.444615384615385,7.155692307692307,7.866769230769231,8.577846153846153,9.288923076923076,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.756,1.3901538461538463,2.0243076923076924,2.6584615384615384,3.2926153846153845,3.9267692307692306,4.5609230769230775,5.195076923076924,5.82923076923077,6.463384615384616,7.097538461538462,7.731692307692308,8.365846153846155,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.756,1.3132307692307692,1.8704615384615384,2.4276923076923076,2.984923076923077,3.5421538461538464,4.099384615384615,4.656615384615384,5.213846153846154,5.771076923076923,6.328307692307693,6.885538461538461,7.442769230769231,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":141.05,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.625,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.756,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >